Welcome to AB Biosciences
Cart 0

Déjà vu Mab

Niche platform technology for life cycle maintenance of approved antibody drugs.


Platform method in engineering of the variable region leads to the second generation antibody drug with increased intrinsic target-binding activity, enhanced therapeutic efficacy, and an extended life cycle maintenance advantage.

PRIM

Recombinant protein as a Pan Fc Receptor Interacting molecule

Cachexian

Cancer treatment via symbiosis with tumor tissues through slowing down the progression of cancer-triggered cachexia.

Abmining

Massive antibody mining, an unique platform for accelerating R&D timelines of therapeutic antibodies.

Déjà vu Mab

Niche platform technology for life cycle maintenance of approved antibody drugs.

NeoCART

Next generation CAR-T modules.